HomeCompareFGEN vs SBUX

FGEN vs SBUX: Dividend Comparison 2026

FGEN yields 22.05% · SBUX yields 2.84%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SBUX wins by $84.3K in total portfolio value· pulled ahead in Year 9
10 years
FGEN
FGEN
● Live price
22.05%
Share price
$9.07
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$82.7K
Annual income
$8,340.12
Full FGEN calculator →
SBUX
SBUX
● Live price
2.84%
Share price
$86.72
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$167.0K
Annual income
$71,136.45
Full SBUX calculator →

Portfolio growth — FGEN vs SBUX

📍 SBUX pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFGENSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FGEN + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FGEN pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FGEN
Annual income on $10K today (after 15% tax)
$1,874.31/yr
After 10yr DRIP, annual income (after tax)
$7,089.10/yr
SBUX
Annual income on $10K today (after 15% tax)
$241.12/yr
After 10yr DRIP, annual income (after tax)
$60,465.98/yr
At 15% tax rate, SBUX beats the other by $53,376.88/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FGEN + SBUX for your $10,000?

FGEN: 50%SBUX: 50%
100% SBUX50/50100% FGEN
Portfolio after 10yr
$124.9K
Annual income
$39,738.29/yr
Blended yield
31.82%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

FGEN
Analyst Ratings
5
Buy
7
Hold
2
Sell
Consensus: Hold
Price Target
$28.00
+208.7% upside vs current
Range: $28.00 — $28.00
Altman Z
-20.3
Piotroski
6/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+19.9% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FGEN buys
0
SBUX buys
0
No recent congressional trades found for FGEN or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFGENSBUX
Forward yield22.05%2.84%
Annual dividend / share$2.00$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$82.7K$167.0K
Annual income after 10y$8,340.12$71,136.45
Total dividends collected$49.4K$136.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusHoldBuy
Analyst price target$28.00$104.00

Year-by-year: FGEN vs SBUX ($10,000, DRIP)

YearFGEN PortfolioFGEN Income/yrSBUX PortfolioSBUX Income/yrGap
1$12,905$2,205.07$11,121$420.68+$1.8KFGEN
2$16,468$2,659.50$12,548$648.40+$3.9KFGEN
3$20,792$3,171.71$14,440$1,013.98+$6.4KFGEN
4$25,990$3,742.62$17,068$1,617.30+$8.9KFGEN
5$32,182$4,372.22$20,912$2,649.52+$11.3KFGEN
6$39,494$5,059.61$26,875$4,499.29+$12.6KFGEN
7$48,062$5,803.04$36,771$8,014.12+$11.3KFGEN
8$58,026$6,599.92$54,542$15,197.11+$3.5KFGEN
9← crossover$69,535$7,446.93$89,602$31,242.49$20.1KSBUX
10$82,743$8,340.12$167,011$71,136.45$84.3KSBUX

FGEN vs SBUX: Complete Analysis 2026

FGENStock

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Full FGEN Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this FGEN vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FGEN vs SCHDFGEN vs JEPIFGEN vs OFGEN vs KOFGEN vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.